|
413 Companies |
|
276 Products |
|
276 Products |
|
144 Mechanisms of Action |
|
557 Trials |
|
45749 News |
|
| «12...625626627628629630631632633634635...645646» |
- |||| oprozomib (ONX 0912) / Amgen
Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Dec 10, 2013
P1/2, N=118, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Not yet recruiting --> Recruiting
- | temozolomide / Generic mfg.
Enrollment change: Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas (clinicaltrials.gov) - Dec 9, 2013
P3, N=201, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Not yet recruiting --> Recruiting N=474 --> 201
- | cisplatin / Generic mfg., nintedanib / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed: A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. (clinicaltrials.gov) - Dec 9, 2013
P1/2, N=16, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=474 --> 201 Recruiting --> Active, not recruiting
- ||| mivavotinib (CB-659) / Calithera
Enrollment open, Metastases: A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies (clinicaltrials.gov) - Dec 8, 2013
P1, N=75, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- carotuximab IV (ENV-105) / Kairos Pharma
Enrollment open, Combination therapy, Metastases: A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 8, 2013
P1b, N=18, Recruiting, Sponsor: Tracon Pharmaceuticals Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (clinicaltrials.gov) - Dec 8, 2013
P2, N=68, Recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- cyclophosphamide / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
New P2 trial: DIPE: Study of Danggui Buxue Decoction in Preventing Neutropenia (clinicaltrials.gov) - Dec 5, 2013
P2, N=50, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- ||||| YPEG-filgrastim (YPEG-rhG-CSF) / Xiamen Amoytop Biotech
New P2 trial: Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy (clinicaltrials.gov) - Dec 5, 2013
P2, N=80, Recruiting, Sponsor: Xiamen Amoytop Biotech Co., Ltd.
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Combination therapy: Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers (clinicaltrials.gov) - Dec 5, 2013
P2, N=108, Active, not recruiting, Sponsor: Belgian Gynaecological Oncology Group
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- alvocidib (DSP-2033) / Sumitomo Pharma
Enrollment closed: Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 5, 2013
P2, N=111, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| albumin-bound paclitaxel / Generic mfg.
Enrollment open: Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors (clinicaltrials.gov) - Dec 4, 2013
P1/2, N=105, Recruiting, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| mivavotinib (CB-659) / Calithera
New P1 trial, Metastases: A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies (clinicaltrials.gov) - Dec 2, 2013
P1, N=75, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
- Qinprezo (vosaroxin) / Denovo
Enrollment open: Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Dec 2, 2013
P1, N=48, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open: A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab) (clinicaltrials.gov) - Dec 2, 2013
P4, N=20, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | alisertib (MLN8237) / Puma
Trial completion, Metastases: A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - Dec 2, 2013
P1, N=36, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Ninlaro (ixazomib) / Takeda
Trial completion: Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma (clinicaltrials.gov) - Dec 2, 2013
P1, N=60, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| oprozomib (ONX 0912) / Amgen
New P1 trial: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 1, 2013
P1/2, N=314, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
- ||| Xalkori (crizotinib) / Pfizer, Inlyta (axitinib) / Pfizer
New P1 trial: A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 1, 2013
P1, N=65, Recruiting, Sponsor: Pfizer
- New P1 trial, Surgery: Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy (clinicaltrials.gov) - Nov 27, 2013
P1, N=30, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- |||||| Gazyva (obinutuzumab) / Roche, Biogen
Enrollment open, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Nov 25, 2013
P3, N=800, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| New P3 trial: Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual (clinicaltrials.gov) - Nov 24, 2013
P3, N=150, Recruiting, Sponsor: Bristol-Myers Squibb
- | cerdulatinib (ALXN2075) / Nicox, AstraZeneca
New P1 trial: Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL (clinicaltrials.gov) - Nov 21, 2013
P1, N=28, Recruiting, Sponsor: Portola Pharmaceuticals
- Telintra (ezatiostat) / MabVax
Trial termination: Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia (clinicaltrials.gov) - Nov 19, 2013
P2, N=9, Terminated, Sponsor: Telik
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Study TLK199.2103 was terminated for business reasons.
- Telintra (ezatiostat) / MabVax
Trial termination, Metastases: Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 19, 2013
P2, N=1, Terminated, Sponsor: Telik
Active, not recruiting --> Terminated; Study TLK199.2103 was terminated for business reasons. Withdrawn --> Terminated; Study TLK199.2102 was terminated for lack of enrollment.
- Telintra (ezatiostat) / MabVax
Trial initiation date, Metastases: Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 19, 2013
P2, N=1, Terminated, Sponsor: Telik
Withdrawn --> Terminated; Study TLK199.2102 was terminated for lack of enrollment. Initiation date: May 2008 --> Oct 2008
- Telintra (ezatiostat) / MabVax
Enrollment change: Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia (clinicaltrials.gov) - Nov 19, 2013
P2, N=9, Terminated, Sponsor: Telik
Initiation date: May 2008 --> Oct 2008 N=20 --> 9
- Telintra (ezatiostat) / MabVax
Enrollment change, Metastases: Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 19, 2013
P2, N=1, Terminated, Sponsor: Telik
N=20 --> 9 N=135 --> 1
- ||||| Tepmetko (tepotinib) / EMD Serono
New P1/2 trial, Monotherapy, Metastases: Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 18, 2013
P1/2, N=158, Recruiting, Sponsor: Merck KGaA
- ||| lorvotuzumab mertansine (IMGN901) / ImmunoGen
Enrollment closed, Combination therapy, Metastases: A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Nov 18, 2013
P1/2, N=145, Active, not recruiting, Sponsor: ImmunoGen, Inc.
N=135 --> 1 Recruiting --> Active, not recruiting
- | Stivarga (regorafenib) / Bayer
Trial completion: Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors. (clinicaltrials.gov) - Nov 18, 2013
P1, N=15, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P3 trial: Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer (clinicaltrials.gov) - Nov 17, 2013
P3, N=30, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- ||||| P1/2 data: Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer (clinicaltrials.gov) - Nov 17, 2013
P1/2, N=150, Recruiting, Sponsor: Onyx Therapeutics, Inc.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 14, 2013
P2, N=72, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=60 --> 72
- || Herceptin (trastuzumab) / Roche, sapanisertib (CB-228) / Calithera
Enrollment closed: Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies (clinicaltrials.gov) - Nov 14, 2013
P1, N=75, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
N=60 --> 72 Recruiting --> Active, not recruiting
- ||| golvatinib (E7050) / Eisai
Enrollment closed, Combination therapy: E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Nov 14, 2013
P1/2, N=95, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Vesanoid (tretinoin) / Roche
New P1/2 trial: Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 13, 2013
P1/2, N=70, Recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| Ogsiveo (nirogacestat) / SpringWorks Therap
Enrollment open, Combination therapy, Metastases: A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer (clinicaltrials.gov) - Nov 13, 2013
P1b, N=60, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Trial completion: Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia (clinicaltrials.gov) - Nov 13, 2013
P1/2, N=87, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Completed
- nintedanib / Generic mfg.
Enrollment change: Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 12, 2013
P1, N=29, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed N=24 --> 29
- | cisplatin / Generic mfg., nintedanib / Generic mfg., gemcitabine / Generic mfg.
Enrollment change: A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. (clinicaltrials.gov) - Nov 12, 2013
P1/2, N=16, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=24 --> 29 N=165 --> 16
- pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg., nintedanib / Generic mfg.
Enrollment closed: BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer (clinicaltrials.gov) - Nov 12, 2013
P1, N=24, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=165 --> 16 Recruiting --> Active, not recruiting
- ||||| Tepmetko (tepotinib) / EMD Serono
New P1/2 trial, Metastases: Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) (clinicaltrials.gov) - Nov 11, 2013
P1/2, N=200, Recruiting, Sponsor: Merck KGaA
- Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: SOLTI-Opti-HER: Study of Neoadjuvant Myocet (clinicaltrials.gov) - Nov 11, 2013
P2, N=83, Active, not recruiting, Sponsor: SOLTI Breast Cancer Research Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || pimasertib (AS703026) / Day One Biopharma
Enrollment closed, Combination therapy, Metastases: EMR 200066-006: Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Nov 11, 2013
P1, N=170, Active, not recruiting, Sponsor: EMD Serono
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche
Enrollment closed: Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma (clinicaltrials.gov) - Nov 10, 2013
P1/2, N=58, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- OCV-501 / Otsuka
Enrollment change: A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Nov 9, 2013
P1, N=9, Completed, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting N=18 --> 9
- OCV-501 / Otsuka
Trial completion: A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Nov 9, 2013
P1, N=9, Completed, Sponsor: Otsuka Pharmaceutical Co., Ltd.
N=18 --> 9 Recruiting --> Completed
- Avastin (bevacizumab) / Roche
Biomarker, New P2 trial: Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients (clinicaltrials.gov) - Nov 7, 2013
P2, N=50, Recruiting, Sponsor: Grupo de Investigaci
- | cyclophosphamide / Generic mfg., carfilzomib / Generic mfg.
P1 data: CHAMPION 2: A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects (clinicaltrials.gov) - Nov 7, 2013
P1, N=27, Recruiting, Sponsor: Onyx Therapeutics, Inc.
- dusigitumab (MEDI-573) / AstraZeneca
Trial completion, Combination therapy, Metastases: MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. (clinicaltrials.gov) - Nov 5, 2013
P1, N=6, Completed, Sponsor: MedImmune LLC
Recruiting --> Completed Active, not recruiting --> Completed